(Editor’s note: The Medicare Payment Advisory Commission (MedPAC) tomorrow will consider a staff analysis of “whether the availability of 340B drug discounts creates incentives to choose more expensive products in some cases and the resulting impact on Medicare patients’ cost-share for such drugs in such cases.” 340B Report plans to be there and fill you in later on what happened.)
Massachusetts Medicaid Wants to Stop Covering “High Cost” Drugs Bought Through 340B
MassHealth, the Massachusetts Medicaid agency, should exercise “great caution” as it decides whether to stop covering unspecified “high cost” drugs bought through the 340B program, the state hospital association warns.
(Editor’s note: The Medicare Payment Advisory Commission (MedPAC) tomorrow will consider a staff analysis of “whether the availability of 340B drug discounts creates incentives to choose more expensive products in some cases and the resulting impact on Medicare patients’ cost-share […]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
